Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
CanSino Biologics, Inc. Class H ( (HK:6185) ) just unveiled an announcement.
CanSino Biologics Inc. has forecasted a notable improvement in its financial performance for 2024, expecting revenues between RMB825.0 million and RMB865.0 million, significantly up from the previous year’s RMB357.1 million. Despite the expected net loss, the results represent a substantial reduction in loss compared to 2023, attributed to increased vaccine commercialization, improved operational efficiency, and cost reductions.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. operates in the biopharmaceutical industry, focusing primarily on the development and commercialization of vaccines. The company is particularly involved in advancing the commercialization of meningococcal conjugate vaccines and developing non-COVID-19 vaccine candidates.
YTD Price Performance: -13.65%
Average Trading Volume: 1,446,139
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$8.96B
See more insights into 6185 stock on TipRanks’ Stock Analysis page.
